Literature DB >> 28839807

A UK cost of care model for inflammatory bowel disease.

Nivedita Ghosh1, Purushothaman Premchand1.   

Abstract

OBJECTIVES: There are an estimated 620 000 patients with inflammatory bowel disease (IBD) in the UK. The rising incidence of IBD combined with its incurability has significant cost implications. The aim of this cost of care model was to calculate the annual cost per adult patient of treating ulcerative colitis (UC) and Crohn's disease (CD) from a NHS perspective, and to enable areas of potential cost savings to be explored.
DESIGN: The cost of IBD was calculated by summing the costs of treatment, treatment side effects and disease-related complications, accounting for the proportions of patients incurring these costs. Default input values for costs, the percentage of patients receiving each treatment, and the percentage of patients experiencing treatment-related side effects or disease-related complications were determined from national sources and published literature. However, the model permitted the user to input local or alternative data.
SETTING: The model was designed to be used by NHS trusts in the UK.
RESULTS: Using default input values, the annual cost of treating any patient with UC was estimated to be £3084. For a patient with UC in remission, in relapse with mild-to-moderate UC or in relapse with severe UC, annual cost per patient was estimated to be £1693, £2903 and £10 760, respectively. The annual cost for any patient with CD was estimated to be £6156 (£1800 for patients in remission; £10 513 for patients in relapse).
CONCLUSIONS: While IBD remains a costly condition with modest potential cost savings, this model facilitates calculation of annual costs per patient with UC and CD, and its customisability will help hospitals identify areas where savings could be made.

Entities:  

Keywords:  CROHN'S DISEASE; INFLAMMATORY BOWEL DISEASE; ULCERATIVE COLITIS

Year:  2015        PMID: 28839807      PMCID: PMC5369575          DOI: 10.1136/flgastro-2014-100514

Source DB:  PubMed          Journal:  Frontline Gastroenterol        ISSN: 2041-4137


  12 in total

1.  Risk factors for surgery and postoperative recurrence in Crohn's disease.

Authors:  O Bernell; A Lapidus; G Hellers
Journal:  Ann Surg       Date:  2000-01       Impact factor: 12.969

2.  Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark.

Authors:  Tine Jess; Lene Riis; Ida Vind; Karen Vanessa Winther; Sixten Borg; Vibeke Binder; Ebbe Langholz; Ole Østergaard Thomsen; Pia Munkholm
Journal:  Inflamm Bowel Dis       Date:  2007-04       Impact factor: 5.325

3.  The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study.

Authors:  C N Bernstein; J F Blanchard; P Rawsthorne; N Yu
Journal:  Am J Gastroenterol       Date:  2001-04       Impact factor: 10.864

4.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis.

Authors:  J A Eaden; K R Abrams; J F Mayberry
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

5.  Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experience.

Authors:  M B Sprakes; A C Ford; N C Suares; L Warren; D Greer; C F Donnellan; J S R Jennings; S M Everett; P J Hamlin
Journal:  Aliment Pharmacol Ther       Date:  2010-10-07       Impact factor: 8.171

6.  Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis.

Authors:  Matthew D Rutter; Brian P Saunders; Kay H Wilkinson; Steve Rumbles; Gillian Schofield; Michael A Kamm; Christopher B Williams; Ashley B Price; Ian C Talbot; Alastair Forbes
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

7.  Health plan utilization and costs of specialty drugs within 4 chronic conditions.

Authors:  Patrick P Gleason; G Caleb Alexander; Catherine I Starner; Stephen T Ritter; Holly K Van Houten; Brent W Gunderson; Nilay D Shah
Journal:  J Manag Care Pharm       Date:  2013-09

8.  Treatment cost of ulcerative colitis is apheresis with Adacolumn cost-effective?

Authors:  J Panés; M Guilera; D Ginard; J Hinojosa; P González-Carro; V González-Lara; V Varea; E Domènech; X Badia
Journal:  Dig Liver Dis       Date:  2007-05-24       Impact factor: 4.088

9.  Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study.

Authors:  A Bassi; S Dodd; P Williamson; K Bodger
Journal:  Gut       Date:  2004-10       Impact factor: 23.059

Review 10.  Guidelines for the management of inflammatory bowel disease in adults.

Authors:  Craig Mowat; Andrew Cole; Al Windsor; Tariq Ahmad; Ian Arnott; Richard Driscoll; Sally Mitton; Tim Orchard; Matt Rutter; Lisa Younge; Charlie Lees; Gwo-Tzer Ho; Jack Satsangi; Stuart Bloom
Journal:  Gut       Date:  2011-05       Impact factor: 23.059

View more
  18 in total

1.  Prognostic tools for identification of high risk in people with Crohn's disease: systematic review and cost-effectiveness study.

Authors:  Steven J Edwards; Samantha Barton; Mariana Bacelar; Charlotta Karner; Peter Cain; Victoria Wakefield; Gemma Marceniuk
Journal:  Health Technol Assess       Date:  2021-03       Impact factor: 4.014

2.  Hydrogen ion changes and contractile behavior in the perfused rat heart.

Authors:  H E Cingolani; A J Maas; A N Zimmerman; F L Meijler
Journal:  Eur J Cardiol       Date:  1975-12

3.  Incidence and prevalence of inflammatory bowel disease in Devon, UK.

Authors:  Ben Hamilton; Harry Green; Neel Heerasing; Peter Hendy; Lucy Moore; Neil Chanchlani; Gareth Walker; Claire Bewshea; Nicholas A Kennedy; Tariq Ahmad; James Goodhand
Journal:  Frontline Gastroenterol       Date:  2020-06-24

Review 4.  Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease.

Authors:  Vassiliki Sinopoulou; Morris Gordon; Anthony K Akobeng; Marco Gasparetto; Michael Sammaan; Jessica Vasiliou; Terence M Dovey
Journal:  Cochrane Database Syst Rev       Date:  2021-11-29

5.  Managing intestinal failure in inflammatory bowel disease - 'when the drugs don't work'.

Authors:  James Morgan; Ashley Bond; Cecil Kullu; Sreedhar Subramanian; Martyn Dibb; Philip J Smith
Journal:  Frontline Gastroenterol       Date:  2020-06-19

6.  The holistic management of consequences of cancer treatment by a gastrointestinal and nutrition team: a financially viable approach to an enormous problem?

Authors:  Ann C Muls; Amyn Lalji; Christopher Marshall; Lewis Butler; Clare Shaw; Susan Vyoral; Kabir Mohammed; H Jervoise N Andreyev
Journal:  Clin Med (Lond)       Date:  2016-06       Impact factor: 2.659

7.  Exploring the role of the microbiota member Bifidobacterium in modulating immune-linked diseases.

Authors:  Ian O'Neill; Zoe Schofield; Lindsay J Hall
Journal:  Emerg Top Life Sci       Date:  2017-11-30

8.  Optimising IBD patient selection for de-escalation of anti-TNF therapy to immunomodulator maintenance.

Authors:  Rachael Swann; Alan Boal; Seth Ian Squires; Carly Lamb; Laura Louise Clark; Selina Lamont; Graham Naismith
Journal:  Frontline Gastroenterol       Date:  2019-05-03

9.  Interventions for the management of abdominal pain in ulcerative colitis.

Authors:  Vassiliki Sinopoulou; Morris Gordon; Terence M Dovey; Anthony K Akobeng
Journal:  Cochrane Database Syst Rev       Date:  2021-07-22

10.  Economic analysis of the adoption of capsule endoscopy within the British NHS.

Authors:  Alan Lobo; Rafael Torrejon Torres; Mark McAlindon; Simon Panter; Catherine Leonard; Nancy van Lent; Rhodri Saunders
Journal:  Int J Qual Health Care       Date:  2020-06-17       Impact factor: 2.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.